Robert Munzinger

Robert Munzinger

Auto-generated profile, based on publicly available information

Robert Munzinger

Medical Faculty, University of Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
FBFelix N. von Brackel
Felix N. von Brackel
RMRobert Munzinger
Robert Munzinger
MBMikolaj Bartosik
Mikolaj Bartosik
ASAlexander Simon
Alexander Simon
FBFlorian Barvencik
Florian Barvencik
MAMichael Amling
Michael Amling
Background: Relative energy deficiency in sport (REDs) is associated with impaired performance and compromised bone health in elite athletes. While reduced bone mineral density (BMD) and increased risk for bone stress injuries are well documented, the underlying metabolic mechanisms remain poorly understood. This study investigates the bone metabolism in athletes with REDs and its impact on BMD and bone microstructure. Methods: We retrospectively analysed data from 82 elite athletes (30.5% females, age 23.4 ± 7.6 years) who presented to our outpatient clinic. The diagnosis of REDs was made according to the International Olympic Committee REDs Clinical Assessment Tool Version 2 (IOC REDs CAT2), and athletes were categorised into strength‐based vs. endurance‐based sports. Laboratory assessment of calcium and bone metabolism included bone turnover markers such as osteocalcin, procollagen type 1 N‐terminal propeptide (P1NP) and urinary deoxypyridinoline (DPD). Areal BMD with corresponding Z ‐score was measured by dual‐energy X‐ray absorptiometry (DXA) at the lumbar spine and hip. Volumetric BMD and bone microstructure were assessed by high‐resolution peripheral quantitative computed tomography (HR‐pQCT) at the distal radius and tibia. Results: REDs was diagnosed in 24% of the athletes, and stress fractures were observed more frequently in athletes with REDs compared with those without REDs (70% vs. 25%, p < 0.001). Athletes with REDs showed significantly lower haemoglobin and haematocrit levels ( p < 0.05). Osteocalcin and P1NP were reduced in REDs compared with athletes of strength‐based disciplines ( p < 0.01), while urinary DPD/creatinine and calcium excretion were elevated ( p < 0.05), indicating suppressed bone formation and increased bone resorption, respectively. Athletes with REDs exhibited significantly reduced Z ‐scores at the lumbar spine and hip compared with strength and endurance athletes without REDs ( p < 0.05). HR‐pQCT revealed significantly lower bone volume to tissue volume and trabecular BMD at the distal radius and tibia, with more pronounced effects at the load‐bearing tibia ( p < 0.01). Similarly, trabecular number and cortical thickness were reduced in REDs, while no differences were observed in trabecular thickness. Conclusion: Athletes with REDs are characterised by a catabolic bone metabolism, marked by reduced bone formation alongside increased bone resorption. The resulting metabolic imbalance compromises skeletal adaptations to mechanical loading and contributes to decreased BMD and deteriorated bone microstructure, particularly at weight‐bearing sites. These findings underscore the shared key features of REDs and cachexia and highlight the need for early identification and management of REDs to prevent bone stress injuries and preserve athletic performance. Monitoring bone metabolism may support targeted treatment and improve outcomes in affected athletes.

20 May 2026 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
TSThomas Schaschinger
Thomas Schaschinger
RMRobert Munzinger
Robert Munzinger
TNTobias Niederegger
Tobias Niederegger
JBJule Brandt
Jule Brandt
FMFabio O. Marcela
Fabio O. Marcela
GHGabriel Hundeshagen
Gabriel Hundeshagen
Background: Given that patients undergoing orthopaedic surgery frequently share risk factors that are associated with metabolic syndrome, the patients orthopaedic surgeons treat may be especially likely to have undiagnosed dysglycemia. Although its broader impact is documented in other specialties, its specific prevalence and association with postoperative outcomes after orthopaedic procedures remains incompletely defined. Quantifying this hidden burden is important to developing individual risk profiles, refining perioperative decision-making, and establishing targeted preoperative medical management strategies for patients considering orthopaedic surgery. Questions/purposes: In a large-database study, we asked: (1) In adults who underwent orthopaedic surgery, what proportion of patients had previously undiagnosed dysglycemia? (2) Was undiagnosed dysglycemia associated with increased odds of 30-day readmission and reoperation compared with patients with normoglycemia? (3) What was the relationship between preoperative HbA1c levels and the 30-day risk of complications in patients who underwent orthopaedic surgery? Methods: Among the 2,990,063 procedures recorded in the American College of Surgeons National Surgical Quality Improvement Program database (2021-2023), 25% (735,259 of 2,990,063) were orthopaedic. After excluding 75% (2,254,804 of 2,990,063) of nonorthopaedic procedures and 16% (493,272 of 2,990,063) of orthopaedic procedures without documented preoperative HbA1c, 8% (241,987 of 2,990,063) of all procedures were analyzed. Patients were assigned to one of eight glycemic groups (normoglycemic, undiagnosed prediabetes, undiagnosed diabetes, or diagnosed diabetes with near-normal, very good, good, poor, and very poor glycemic control) based on diabetes diagnosis and HbA1c level. The study cohort included patients undergoing a range of procedures, primarily consisting of total joint arthroplasty, fracture fixation, and spine surgery. The mean ± SD patient age was 66 ± 12 years and 56% [134,741 of 241,987] of patients were female. To address the first research question, the percentage of patients with previously undiagnosed dysglycemia in each cohort was measured, supplemented by a best-case sensitivity analysis to provide a conservative estimate for the entire surgical population. The second and third research questions investigated the association of undiagnosed dysglycemia on 30-day odds of readmission and reoperation and the relationship between preoperative HbA1c and 30-day odds of complications, using multivariable logistic regression adjusted for demographic, comorbidity, and procedural factors. To illustrate variation across operations, the 30-day complication rate of patients across HbA1c strata was evaluated for the 10 most frequent primary Current Procedural Terminology–coded procedures. Results: We found that 22% (52,609 of 241,987) of patients with a recorded preoperative HbA1c had undiagnosed prediabetes and 4% (10,690 of 241,987) of patients met the criteria for undiagnosed diabetes. In a best-case sensitivity analysis in which we assumed that all patients without an HbA1c measurement did not have diabetes and had normoglycemia, the smallest percentage of patients with previously undiagnosed dysglycemia would have been 9% (63,299) across all 735,259 patients who underwent orthopaedic surgery. After adjusting for potentially confounding variables, neither prediabetes nor diabetes was independently associated with increased odds of 30-day readmission (adjusted OR 0.95 [95% CI 0.88 to 1.0]; p = 0.12 and adjusted OR 0.99 [95% CI 0.84 to 1.2]; p = 0.94) or reoperation (adjusted OR 0.94 [95% CI 0.85 to 1.0]; p = 0.25 and adjusted OR 0.99 [95% CI 0.84 to 1.2]; p = 0.94) compared with patients with normoglycemia. The adjusted ORs for any 30-day complication were higher in patients with undiagnosed diabetes (adjusted OR 1.1 [95% CI 1.0 to 1.2]; p = 0.03) and increased across HbA1c strata in those with diagnosed diabetes (adjusted OR 1.2, 1.1, 1.2, 1.4, and 2.0; all p ≤ 0.009) compared with patients with normoglycemia. Procedure-level analyses showed consistent patterns with variable magnitude: 30-day rates of any complication in THA rose from 5% (1425 of 27,812) to 17% (49 of 294) across HbA1c strata, whereas 30-day complication rates peaked at 30% (203 of 675) in hinged TKA and at 22% (11 of 49) in revision TKA. On the other hand, 30-day complication rates in shoulder procedures and knee arthroscopy remained uniformly low (< 6%) with minimal variation by HbA1c. Conclusion: Unrecognized dysglycemia is common among patients undergoing orthopaedic surgery and is associated with postoperative morbidity. Selective preoperative HbA1c assessment and procedure-specific targets may improve perioperative risk stratification. Examining these effects in clinical studies with procedure-specific preoperative HbA1c screening to identify and appropriately treat patients at risk could help to further validate these findings. Level of Evidence: Level III, therapeutic study.